Tag: seasonal influenza market forecast

Uncover key drivers, emerging technologies, and competitive movements shaping the seasonal influenza market from 2026–2035 with trusted insights from The Business Research Company

What is the expected shift in the Seasonal Influenza Market’s size between 2026 and 2030?

The seasonal influenza market’s valuation has shown rapid expansion over recent years. It is anticipated to grow from $9.85 billion in 2025 to $11.53 billion in 2026, progressing at a compound annual growth rate (CAGR) of 17.1%. The growth observed in prior periods can be attributed to seasonal flu outbreaks, limited vaccine coverage, conventional diagnostics, low public awareness, and regional distribution challenges.

The seasonal influenza market is anticipated to experience significant expansion in the coming years. By 2030, this market is projected to reach $21.39 billion, exhibiting a compound annual growth rate (CAGR) of 16.7%. This projected expansion stems from factors such as the advancement of universal vaccines, the widespread adoption of rapid point-of-care diagnostics, enhanced digital immunization tracking, collaborative public-private vaccination campaigns, and improvements in supply chain optimization. Key developments shaping the market during this period encompass universal flu vaccines, efficient rapid diagnostic tests, the emergence of home-based vaccination services, a rise in government-led immunization initiatives, and the modernization of the pharmaceutical supply chain.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21285&type=smp

Which Drivers Are Shaping Strategic Decisions In The Seasonal Influenza Market?

The seasonal influenza market is expected to expand due to the rising prevalence of respiratory infections. These infections are conditions caused by viruses or bacteria that affect the respiratory system, including the sinuses, throat, airways, or lungs. The increasing occurrence of respiratory infections is driven by factors such as air pollution, changing climates, weakened immune responses, and the ease of viral transmission in crowded or poorly ventilated environments. Seasonal influenza treatment aids in preventing or reducing the severity of respiratory infections in multiple ways, primarily by targeting the influenza virus and managing symptoms that could lead to secondary infections. For instance, in October 2024, according to the UK Health Security Agency, a UK-based government agency, the number of tuberculosis (TB) (a respiratory infection caused by the bacterium Mycobacterium tuberculosis) cases in England experienced a 10.7% year-over-year increase in 2023, rising from 4,380 cases in 2022 to 4,850 cases. Therefore, the increase in respiratory infections will stimulate the growth of the seasonal influenza market.

What Segment Classifications Make Up The Seasonal Influenza Market?

The seasonal influenza market covered in this report is segmented –

1) By Type: Influenza A Virus, Influenza B Virus, Influenza C Virus, Influenza D Virus

2) By Route Of Administration: Parenteral, Oral, Other Route Of Administrations

3) By Distribution Channel: Hospital, Government And institutional supply, Pharmacy, Online

4) By Treatment: Antiviral, Neuraminidase Inhibitors, Vaccination, Other Treatments

Subsegments:

1) By Influenza A Virus: Subtype H1N1, Subtype H3N2, Other Subtypes

2) By Influenza B Virus: Lineage Victoria, Lineage Yamagata

3) By Influenza C Virus: Seasonal C Virus, Non-seasonal C Virus

4) By Influenza D Virus: Animal-associated Influenza D, Zoonotic Surveillance And Research Applications

What Trends Are Reshaping The Dynamics Of The Seasonal Influenza Market?

Leading companies within the seasonal influenza market are prioritizing progress in treatments, specifically combination vaccines, to boost immunity by addressing multiple viral strains, thereby increasing efficacy and lessening the requirement for repeated immunizations. These combination vaccines offer protection against several diseases or strains through one injection, which consequently decreases the total number of vaccinations necessary. An example of this is seen in October 2023, when Moderna, Inc., a biotechnology firm based in the US, reported favorable interim Phase 1/2 trial outcomes for mRNA-1083, its experimental combination vaccine designed to target both influenza and COVID-19. Intended to improve adherence, simplify administration, and offer greater convenience for patients and healthcare providers, mRNA-1083 is currently undergoing assessment for its safety and immunogenicity, measured against standard flu vaccines Fluarix (ages 50-64) and Fluzone HD (ages 65-79), in addition to a comparison with the Spikevax booster.

Which Major Firms Are Strengthening Their Position In The Seasonal Influenza Market?

Major companies operating in the seasonal influenza market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Sanofi S.A., AstraZeneca PLC, Novartis International AG, GlaxoSmithKline plc, Merck KGaA, Moderna Inc., Boehringer Ingelheim International GmbH, Sinovac Biotech Ltd., Daiichi Sankyo Company Limited, CSL Limited, Genentech Inc., Shionogi & Co. Ltd., Emergent BioSolutions Inc., Novavax Inc., BioCryst Pharmaceuticals Inc., Bharat Biotech International Limited, Vaxart Inc., Inovio Pharmaceuticals Inc., SK bioscience Co. Ltd., Mitsubishi Tanabe Pharma Corporation, FluGen Inc., Altimmune Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/seasonal-influenza-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Seasonal Influenza Market?

North America was the largest region in the seasonal influenza market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the seasonal influenza market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Seasonal Influenza Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21285&type=smp

Browse Through More Reports Similar to the Global Seasonal Influenza Market 2026, By The Business Research Company

Swine Flu Vaccination Market Report 2026

https://www.thebusinessresearchcompany.com/report/swine-flu-vaccination-global-market-report

Influenza Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/influenza-vaccines-global-market-report

Influenza Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/influenza-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What Are The Market Size Estimates For The Seasonal Influenza Market?

In recent times, the size of the seasonal influenza market has experienced rapid expansion. It’s predicted to increase from $8.41 billion in 2024 to $9.85 billion in 2025, showcasing a compound annual growth rate (CAGR) of 17.1%. Factors that have contributed to the growth during the historical period include a higher prevalence of influenza, an expanding elderly population, an uptick in infectious and chronic diseases, an escalating burden of illnesses related to influenza, and an increase in respiratory infections.

Expect a swift expansion in the seasonal influenza market size in the upcoming years, as it’s projected to reach $18.39 billion in 2029, boasting a compound annual growth rate (CAGR) of 16.9%. The expected growth during the forecast period can be credited to factors such as the growing demand for oral medication solutions, the rise in research and development activities, increased rates of vaccination, enhancement in healthcare infrastructure, and the increased need for retail pharmacies. Key trends to watch for during this period include improvements in treatment and technology, breakthroughs in vaccine and mRNA technology, along with advancements in digital health solutions for monitoring and diagnosis.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21285&type=smp

Which Industry Forces Are Driving The Seasonal Influenza Market Forward?

The growing occurrence of respiratory infections is anticipated to drive the advancement of the seasonal influenza market. Respiratory infections, which are diseases triggered by viruses or bacteria impacting the respiratory system such as the sinuses, throat, airways, or lungs, are on the rise. Factors such as air pollution, changing weather conditions, diminished immune reactions, and the quick spread of viruses in congested or poorly aired areas are contributing to this increase. Seasonal flu treatments aid in preventing or lessening the harshness of these respiratory infections in numerous ways, mainly by attacking the flu virus and controlling symptoms that may lead to other infections. For example, in October 2024, the UK Health Security Agency, a government agency in the UK, reported that the instance of tuberculosis (TB) (a respiratory infection prompted by the bacterium Mycobacterium tuberculosis) cases saw an annual increase of 10.7% in 2023 in England, escalating from 4,380 cases in 2022 to 4,850 cases. Consequently, these escalating respiratory infection figures will contribute to the development of the seasonal influenza market.

How Is The Seasonal Influenza Market Organized By Different Segments?

The seasonal influenzamarket covered in this report is segmented –

1) By Type: Influenza A Virus; Influenza B Virus; Influenza C Virus; Influenza D Virus

2) By Route Of Administration: Parenteral; Oral; Other Route Of Administrations

3) By Distribution Channel: Hospital; Government and institutional supply; Pharmacy; Online

4) By Treatment: Antiviral; Neuraminidase Inhibitors; Vaccination; Other Treatments

Subsegments:

1) By Influenza A Virus: Subtype H1N1; Subtype H3N2; Other Subtypes

2) By Influenza B Virus: Lineage Victoria; Lineage Yamagata

3) By Influenza C Virus: Seasonal C Virus; Non-seasonal C Virus

4) By Influenza D Virus: Animal-associated Influenza D

What Current And Upcoming Trends Are Shaping The Seasonal Influenza Market?

In the seasonal influenza market, key players are focusing on combination vaccines to strengthen immunity by targeting multiple virus strains, boosting vaccine efficacy and reducing vaccination frequency. Combination vaccines protect against several diseases or strains through a single injection, simplifying immunization schedules. For instance, in October 2023, US biotechnology company Moderna announced encouraging interim Phase 1/2 trial results for mRNA-1083, a combination vaccine targeting both influenza and COVID-19. Designed to improve compliance and convenience, this vaccine is being evaluated against standard flu vaccines such as Fluarix and Fluzone HD, as well as the Spikevax booster.

Who Are The Primary Market Leaders In The Seasonal Influenza Market?

Major companies operating in the seasonal influenza market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Sanofi S.A., AstraZeneca PLC, Novartis International AG, GlaxoSmithKline plc, Merck KGaA, Moderna Inc., Boehringer Ingelheim International GmbH, Sinovac Biotech Ltd., Daiichi Sankyo Company Limited, CSL Limited, Genentech Inc., Shionogi & Co. Ltd., Emergent BioSolutions Inc., Novavax Inc., BioCryst Pharmaceuticals Inc., Bharat Biotech International Limited, Vaxart Inc., Inovio Pharmaceuticals Inc., SK bioscience Co. Ltd., Mitsubishi Tanabe Pharma Corporation, FluGen Inc., Altimmune Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/seasonal-influenza-global-market-report

How Do Regional Dynamics Influence The Seasonal Influenza Market Performance?

North America was the largest region in the seasonal influenza market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the seasonal influenza market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=21285&type=smp

Browse Through More Reports Similar to the Global Seasonal Influenza Market 2025, By The Business Research Company

Influenza Diagnostic Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/influenza-diagnostic-global-market-report

Influenza Vaccines Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/influenza-vaccines-global-market-report

Virus Filtration Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/virus-filtration-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Is The Seasonal Influenza Market Size Likely To Evolve From 2025 Through 2034?

The seasonal influenza market has seen rapid expansion in recent years. It is projected to increase from $8.41 billion in 2024 to $9.85 billion in 2025, at a compound annual growth rate (CAGR) of 17.1%. This historical growth can be linked to the increasing occurrence of influenza, a growing older demographic, a rise in infectious and chronic diseases, the escalating burden of illnesses associated with influenza, and an increase in respiratory infections.

The seasonal influenza market size is projected to undergo significant expansion in the coming years. It is forecast to achieve a size of $18.39 billion by 2029, growing at a compound annual growth rate (CAGR) of 16.9%. This expansion during the forecast period can be attributed to an elevated demand for oral drug solutions, increased research and development initiatives, a rise in vaccination numbers, enhancements in healthcare infrastructure, and an escalating need for retail pharmacies. Prominent trends for the forecast period encompass advancements in treatment, technological progress, developments in vaccine technology, the integration of mRNA technology, and digital health solutions for monitoring and diagnosis.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21285&type=smp

Which Drivers Are Shaping The Seasonal Influenza Industry’s Market Share?

A projected increase in respiratory infections is anticipated to drive the expansion of the seasonal influenza market in the future. These infections are defined as conditions resulting from viral or bacterial agents that impact the respiratory tract, encompassing areas such as the sinuses, throat, airways, or lungs. The rising incidence of respiratory infections stems from factors like air pollution, shifting climates, compromised immune systems, and the effortless spread of viruses in congested or inadequately ventilated environments. Seasonal influenza therapies contribute to preventing or mitigating the severity of respiratory infections through various mechanisms, predominantly by targeting the influenza virus and controlling symptoms that might progress into secondary infections. As an illustration, in October 2024, data from the UK Health Security Agency, a UK-based government body, revealed that instances of tuberculosis (TB)—a respiratory infection caused by the bacterium Mycobacterium tuberculosis—in England saw a 10.7% year-over-year increase in 2023, escalating from 4,380 cases in 2022 to 4,850 cases. Consequently, this upsurge in respiratory infections will fuel the growth of the seasonal influenza market.

What Are The Major Segments Identified In The Seasonal Influenza Market?

The seasonal influenzamarket covered in this report is segmented –

1) By Type: Influenza A Virus; Influenza B Virus; Influenza C Virus; Influenza D Virus

2) By Route Of Administration: Parenteral; Oral; Other Route Of Administrations

3) By Distribution Channel: Hospital; Government and institutional supply; Pharmacy; Online

4) By Treatment: Antiviral; Neuraminidase Inhibitors; Vaccination; Other Treatments

Subsegments:

1) By Influenza A Virus: Subtype H1N1; Subtype H3N2; Other Subtypes

2) By Influenza B Virus: Lineage Victoria; Lineage Yamagata

3) By Influenza C Virus: Seasonal C Virus; Non-seasonal C Virus

4) By Influenza D Virus: Animal-associated Influenza D

What Long-Term Trends Will Shape The Future Growth Of The Seasonal Influenza Industry?

Companies operating within the seasonal influenza market are concentrating on advancements in treatment, particularly combination vaccines, to boost immunity by targeting multiple viral strains, thereby enhancing effectiveness and reducing the necessity for frequent vaccinations. These combination vaccines provide protection against various diseases or strains with a single injection, thus decreasing the total number of shots required for immunization. For illustration, in October 2023, Moderna, Inc., a US-based biotechnology company, announced encouraging interim Phase 1/2 trial results for mRNA-1083, its investigational combination vaccine aimed at both influenza and COVID-19. Developed to improve compliance, streamline administration, and offer greater convenience for individuals and healthcare systems, mRNA-1083 is presently being evaluated for safety and immunogenicity in comparison to standard flu vaccines Fluarix (ages 50-64) and Fluzone HD (ages 65-79), alongside a comparison to the Spikevax booster.

Which Key Market Players Are Investing In Expansion And Innovation Of Seasonal Influenza Market?

Major companies operating in the seasonal influenza market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Sanofi S.A., AstraZeneca PLC, Novartis International AG, GlaxoSmithKline plc, Merck KGaA, Moderna Inc., Boehringer Ingelheim International GmbH, Sinovac Biotech Ltd., Daiichi Sankyo Company Limited, CSL Limited, Genentech Inc., Shionogi & Co. Ltd., Emergent BioSolutions Inc., Novavax Inc., BioCryst Pharmaceuticals Inc., Bharat Biotech International Limited, Vaxart Inc., Inovio Pharmaceuticals Inc., SK bioscience Co. Ltd., Mitsubishi Tanabe Pharma Corporation, FluGen Inc., Altimmune Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/seasonal-influenza-global-market-report

Which Region Shows The Highest Potential For Future Expansion In The Seasonal Influenza Market?

North America was the largest region in the seasonal influenza market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the seasonal influenza market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Seasonal Influenza Market Report:

https://www.thebusinessresearchcompany.com/customise?id=21285&type=smp

Browse Through More Reports Similar to the Global Seasonal Influenza Market 2025, By The Business Research Company

Influenza Diagnostic Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/influenza-diagnostic-global-market-report

Influenza Vaccines Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/influenza-vaccines-global-market-report

Virus Filtration Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/virus-filtration-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Key Milestones in the Seasonal Influenza Market’s Growth Trajectory From 2025 To 2034?

The market size of seasonal influenza has seen a swift expansion in the past few years. The increase is projected to go from $8.41 billion in 2024 to about $9.85 billion by 2025, indicating a compound annual growth rate (CAGR) of 17.1%. The significant growth during the historic phase can be credited to factors such as increased incidence of influenza, growing older population, increased occurrence of infectious and chronic diseases, heightened strain due to illness related to influenza, and an increase in respiratory infections.

Anticipations are high for a swift expansion of the seasonal influenza market in the upcoming years. Predictions indicate the growth to reach$18.39 billion by 2029″ moving at a compound annual growth rate (CAGR) of 16.9%. This amplified growth during the forecast period can be connected to increasing demands for oral drug treatments, intensifying research and developmental programs, a rise in vaccination numbers, enhanced healthcare infrastructure, and amplified demand in retail pharmacies. Notable trends for the forecast period involve progress in treatment methods, technological advancement, progress in vaccine technology, mRNA technology, and the introduction of digital health solutions for monitoring and diagnosis.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21285&type=smp

What Are the Core Market Drivers Propelling Growth in the Seasonal Influenza Industry?

The escalating occurrence of respiratory infections is anticipated to spur the expansion of the seasonal influenza market in the future. Respiratory illnesses are infections instigated by viruses or bacteria affecting the respiratory system, including the lungs, airways, throat, and sinuses. The escalated occurrence of such infections is triggered by factors like air pollution, fluctuating weather conditions, compromised immune responses, and easy transmission of viruses in crowded or improperly ventilated areas. Seasonal influenza treatment is instrumental in curtailing or lessening the intensity of these infections in several manners, primarily through its focus on the influenza virus and management of symptoms that can catalyze secondary infections. For example, as per the UK Health Security Agency, a governmental body based in the UK, there was an annual increase of 10.7% in the number of tuberculosis (a respiratory infection effects due to the bacterium called Mycobacterium tuberculosis) cases in England in October 2024, soaring up from 4,380 cases in 2022 to 4,850 cases in 2023. Thus, the surge in respiratory infections is predicted to stimulate the growth of the seasonal influenza market.

How Is the Seasonal Influenza Market Segmented?

The seasonal influenzamarket covered in this report is segmented –

1) By Type: Influenza A Virus; Influenza B Virus; Influenza C Virus; Influenza D Virus

2) By Route Of Administration: Parenteral; Oral; Other Route Of Administrations

3) By Distribution Channel: Hospital; Government and institutional supply; Pharmacy; Online

4) By Treatment: Antiviral; Neuraminidase Inhibitors; Vaccination; Other Treatments

Subsegments:

1) By Influenza A Virus: Subtype H1N1; Subtype H3N2; Other Subtypes

2) By Influenza B Virus: Lineage Victoria; Lineage Yamagata

3) By Influenza C Virus: Seasonal C Virus; Non-seasonal C Virus

4) By Influenza D Virus: Animal-associated Influenza D

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=21285&type=smp

Which Regions Are Driving the Next Phase of the Seasonal Influenza Market Growth?

North America was the largest region in the seasonal influenza market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the seasonal influenza market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Key Market Trends and Innovations Are Shaping the Future of the Seasonal Influenza Industry?

Prominent firms working in the market for seasonal influenza are emphasizing the progression of treatments such as combined vaccines. These vaccines aim to augment immunity by targeting multiple virus strains, increasing the overall efficiency and reducing the necessity for regular vaccinations. Combining vaccines gives protection against various diseases or strains through a single shot, therefore reducing the needed number of vaccinations for immunization. For example, Moderna, Inc., a biotechnology company based in the US, declared promising interim results for Phase 1/2 trials for mRNA-1083, its experimental mixed vaccine against influenza and COVID-19 in October 2023. The design of mRNA-1083 aims to amplify adherence, simplify management, and enhance convenience for individuals and health care structures. It’s currently under evaluation for safety and immunogenicity against standard flu vaccines Fluarix (for ages 50-64) and Fluzone HD (for ages 65-79), and is also being compared with the Spikevax booster.

View the full report here:

https://www.thebusinessresearchcompany.com/report/seasonal-influenza-global-market-report

How Is the Seasonal Influenza Market Defined and What Are Its Core Parameters?

Seasonal influenza, commonly known as the flu, is a contagious respiratory infection caused by influenza viruses that circulate globally, primarily during specific seasons (typically fall and winter in temperate regions). It spreads through respiratory droplets when an infected person coughs, sneezes, or talks. Seasonal influenza leads to widespread illness and can result in serious complications, particularly for vulnerable populations such as the elderly and those with weakened immune systems.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21285

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Seasonal Influenza Market Grown from 2024 to 2025?

The market size for seasonal influenza has seen swift enlargement in recent history. Projected growth figures indicate an increase from $8.41 billion in 2024 to $9.88 billion in 2025, indicating a compound annual growth rate (CAGR) of 17.4%. This significant growth during the historical period can be ascribed to several factors. These include an increase in cases of influenza, a growth in the aged population, an increase in the frequency of infectious and chronic diseases, a mounting impact of illnesses related to influenza, and a rise in respiratory infections.

What Growth Rate Is Anticipated for the Seasonal Influenza Market in the Coming Years?

It is anticipated that the market size for seasonal influenza will experience quick expansion in the coming years, reaching $18.55 billion in 2029 with a compound annual growth rate (CAGR) of 17.1%. The surge during the predictive period is due to a rising requirement for oral medication solutions, escalated R&D efforts, a growth in vaccine numbers, enhanced healthcare facilities, and a growing need for retail pharmacies. Key trends expected during the forecast period encompass progress in treatment methods, technological advancements, evolution in vaccine technology, mRNA technology, and digital health solutions for monitoring and diagnosis.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21285&type=smp

Who Are the Leading Companies in the Seasonal Influenza Market?

Major companies operating in the seasonal influenza market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Sanofi S.A., AstraZeneca PLC, Novartis International AG, GlaxoSmithKline plc, Merck KGaA, Moderna Inc., Boehringer Ingelheim International GmbH, Sinovac Biotech Ltd., Daiichi Sankyo Company Limited, CSL Limited, Genentech Inc., Shionogi & Co. Ltd., Emergent BioSolutions Inc., Novavax Inc., BioCryst Pharmaceuticals Inc., Bharat Biotech International Limited, Vaxart Inc., Inovio Pharmaceuticals Inc., SK bioscience Co. Ltd., Mitsubishi Tanabe Pharma Corporation, FluGen Inc., Altimmune Inc.

What Are the Key Drivers of the Seasonal Influenza Market?

The rise in respiratory infections is set to fuel the expansion of the seasonal influenza market. These infections, resulting from viruses or bacteria, impact the respiratory system, encompassing the sinuses, throat, airways, or lungs. Factors contributing to the growing number of respiratory infections include air pollution, variations in climate, reduced immune responses, and the ease of spreading viruses in congested or inadequately ventilated spaces. The treatment for seasonal influenza provides various ways to avert or lessen the intensity of respiratory infections, mainly by targeting the influenza virus and managing the symptoms that can result in secondary infections. For example, the UK Health Security Agency, a government agency in the UK, reported that in October 2024, tuberculosis (TB) cases in England – a respiratory infection caused by the bacterium Mycobacterium tuberculosis – saw an annual increase of 10.7% in 2023, growing from 4,380 cases in 2022 to 4,850 cases. As such, the surge in respiratory infections is anticipated to foster the development of the seasonal influenza market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=21285&type=smp

What Are the Key Market Segments in the Seasonal Influenza Industry?

The seasonal influenza market covered in this report is segmented –

1) By Type: Influenza A Virus, Influenza B Virus, Influenza C Virus, Influenza D Virus

2) By Route Of Administration: Parenteral, Oral, Other Route Of Administrations

3) By Distribution Channel: Hospital, Government and institutional supply, Pharmacy, Online

4) By Treatment: Antiviral, Neuraminidase Inhibitors, Vaccination, Other Treatments

Subsegments:

1) By Influenza A Virus: Subtype H1N1, Subtype H3N2, Other Subtypes

2) By Influenza B Virus: Lineage Victoria, Lineage Yamagata

3) By Influenza C Virus: Seasonal C Virus, Non-seasonal C Virus

4) By Influenza D Virus: Animal-associated Influenza D

What Are the Latest Trends in the Seasonal Influenza Market?

Leading firms operating in the seasonal influenza market are directing their efforts towards innovation in treatment methods, like combination vaccines, to bolster immunity by addressing multiple variants of the virus. This enhances the efficiency and downplays the requirement for regular vaccinations. Combination vaccines counteract multiple illnesses or different strains with just one inoculation, which brings down the count of jabs necessary for immunization. For instance, Moderna, Inc., an American biotech firm, made an announcement in October 2023, revealing encouraging early Phase 1/2 trial outcomes for mRNA-1083, their experimental combination vaccine tackling both flu and COVID-19. mRNA-1083 is designed to boost compliance, simplify management and enhance convenience for both individuals and healthcare systems. Currently, it’s being assessed for safety and ability to prompt an immune response in comparison to standard flu vaccines like Fluarix (for age group 50-64) and Fluzone HD (for age group 65-79), and also against the Spikevax booster.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/seasonal-influenza-global-market-report

What Are the Key Regional Markets in the Seasonal Influenza Industry?

North America was the largest region in the seasonal influenza market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the seasonal influenza market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21285

This Report Delivers Insight On:

1. How big is the seasonal influenza market, and how is it changing globally?

2. Who are the major companies in the seasonal influenza market, and how are they performing?

3. What are the key opportunities and risks in the seasonal influenza market right now?

4. Which products or customer segments are growing the most in the seasonal influenza market?

5. What factors are helping or slowing down the growth of the seasonal influenza market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.

#What Is the Estimated Market Size of the Seasonal Influenza Market In 2029?#_x000D_

In recent times, there has been a quick expansion of the seasonal influenza market size. The market is projected to escalate from $8.41 billion in 2024 to $9.88 billion in 2025, showcasing a compound annual growth rate (CAGR) of 17.4%. This significant growth in the past period can be traced back to the increasing occurrences of influenza, the surge in the aging population, a rise in infectious and chronic disease prevalence, increasing incidences of ailments related to influenza, and augmenting respiratory infections._x000D_

_x000D_

In the coming years, rapid expansion is forecasted in the seasonal influenza market, with predictions estimating a growth to $18.55 billion by 2029, maintaining a compound annual growth rate (CAGR) of 17.1%. This growth within the projected period can be linked to several factors, including a rising demand for oral drug treatments, significant advances in research and development, a surge in vaccination numbers, enhancements in healthcare facilities, and a growing preference for retail pharmacies. The forecasted period also signals prominent trends including progression in treatments, modern technological advancements, upgrades in vaccine technology, developments in mRNA technology, and the use of digital health solutions for monitoring and diagnosing._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=21285&type=smp_x000D_

_x000D_

#What are the Fundamental Drivers and Innovations Shaping the Seasonal Influenza Market?#_x000D_

The escalating frequency of respiratory illnesses is projected to fuel the expansion of the seasonal influenza market in the future. Respiratory ailments, which affect the sinuses, throat, airways, or lungs, are caused by viruses or bacteria. The surge in these infections is linked to factors such as air pollution, climate changes, compromised immune systems, and the propensity for viruses to spread easily in crowded or inadequately ventilated environments. Seasonal flu treatments can help to curb or lessen the severity of these respiratory illnesses by addressing the flu virus and managing symptoms which may cause further infection. As an example, the UK Health Security Agency, a government organization in the United Kingdom, recorded a 10.7% annual increase in tuberculosis (TB) cases (an infection resulting from the bacterium Mycobacterium tuberculosis) in England in October 2024. The cases rose from 4,380 in 2022 to 4,850. Consequently, this surge in respiratory illnesses will stimulate the expansion of the seasonal influenza market._x000D_

_x000D_

#How Is the Seasonal Influenza Market Segmented?#_x000D_

The seasonal influenza market covered in this report is segmented –_x000D_

_x000D_

1) By Type: Influenza A Virus, Influenza B Virus, Influenza C Virus, Influenza D Virus_x000D_

2) By Route Of Administration: Parenteral, Oral, Other Route Of Administrations_x000D_

3) By Distribution Channel: Hospital, Government and institutional supply, Pharmacy, Online_x000D_

4) By Treatment: Antiviral, Neuraminidase Inhibitors, Vaccination, Other Treatments_x000D_

_x000D_

Subsegments:_x000D_

1) By Influenza A Virus: Subtype H1N1, Subtype H3N2, Other Subtypes_x000D_

2) By Influenza B Virus: Lineage Victoria, Lineage Yamagata_x000D_

3) By Influenza C Virus: Seasonal C Virus, Non-seasonal C Virus_x000D_

4) By Influenza D Virus: Animal-associated Influenza D_x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=21285&type=smp_x000D_

_x000D_

#Which Regions Are Driving the Next Phase of the Seasonal Influenza Market Growth?#_x000D_

North America was the largest region in the seasonal influenza market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the seasonal influenza market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#What Key Trends Are Shaping the Future of the Seasonal Influenza Market?#_x000D_

Leading companies in the seasonal influenza market are directing their efforts toward innovative treatments, including combination vaccines, to strengthen immune response by tackling multiple virus strains, ameliorating effectiveness, and minimizing the requirement for regular vaccinations. Combination vaccines provide defense against numerous diseases or strains through a single inoculation, lessening the shots required for immunization. For example, Moderna, Inc., a biotech company from the US, disclosed favorable preliminary results for Phase 1/2 trial of mRNA-1083, a combination vaccine under investigation, targeting both influenza and COVID-19 in October 2023. mRNA-1083, aimed at increasing compliance, streamlining administration, and intimately upping convenience for patients and healthcare systems, is being tested for safety and immunogenicity against conventional flu vaccines such as Fluarix (ages 50-64) and Fluzone HD (ages 65-79). This is besides its comparison with the Spikevax booster._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/seasonal-influenza-global-market-report_x000D_

_x000D_

#How Is the Seasonal Influenza Market Defined and What Are Its Core Parameters?#_x000D_

Seasonal influenza, commonly known as the flu, is a contagious respiratory infection caused by influenza viruses that circulate globally, primarily during specific seasons (typically fall and winter in temperate regions). It spreads through respiratory droplets when an infected person coughs, sneezes, or talks. Seasonal influenza leads to widespread illness and can result in serious complications, particularly for vulnerable populations such as the elderly and those with weakened immune systems._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21285_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 3156230293_x000D_

Asia +44 2071930708_x000D_

Europe +44 2071930708_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

How Are Key Drivers Contributing to the Growth and Expansion of the Seasonal Influenza Market?

The growing prevalence of respiratory infections is expected to propel the growth of the seasonal influenza market in the future. Respiratory infections are illnesses caused by viruses or bacteria that affect the respiratory system, including the sinuses, throat, airways, or lungs. The rising prevalence of respiratory infections is driven by factors such as air pollution, changing climates, weakened immune responses, and the ease of viral transmission in crowded or poorly ventilated spaces. Seasonal influenza treatment helps prevent or reduce the severity of respiratory infections by addressing the influenza virus and managing symptoms that can lead to secondary infections. For example, in October 2024, the UK Health Security Agency, a U.K.-based government body, reported that tuberculosis (TB) cases in England had risen by 10.7% year-over-year in 2023, increasing from 4,380 cases in 2022 to 4,850 cases. Therefore, the rise in respiratory infections is expected to drive the growth of the seasonal influenza market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21285&type=smp

How Will the Growth Rate of theSeasonal Influenza Market Impact Industry Trends by 2034?

The seasonal influenza market has grown rapidly, increasing from $8.41 billion in 2024 to $9.88 billion in 2025 at a CAGR of 17.4%. This growth is driven by the rising prevalence of influenza, an aging population, a higher incidence of infectious and chronic diseases, an increasing burden of influenza-related illnesses, and a surge in respiratory infections.

The seasonal influenza market is expected to see rapid growth, reaching $18.55 billion by 2029 at a CAGR of 17.1%. The forecasted expansion is attributed to the increasing demand for oral drug solutions, expanding research and development activities, growing vaccination rates, improvements in healthcare infrastructure, and a rising need for retail pharmacy solutions. Major trends include advancements in treatment methods, technological innovations, progress in vaccine development, expansion of mRNA-based technology, and the adoption of digital health solutions for monitoring and diagnosis.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21285

What New Market Trends Are Reshaping theSeasonal Influenza Market and Its Opportunities?

Major companies in the seasonal influenza market are developing combination vaccines to improve immunity by targeting multiple strains of the flu virus and reducing the need for frequent vaccinations. Combination vaccines protect against several diseases or strains with one injection, streamlining the immunization process. For instance, in October 2023, Moderna announced positive Phase 1/2 trial results for mRNA-1083, an investigational combination vaccine targeting both influenza and COVID-19. This vaccine aims to enhance compliance and simplify administration, offering an integrated solution to protect against multiple infections.

Who Are the Leading Market Players Fueling Growth in the Seasonal Influenza Market Trend?

Major companies operating in the seasonal influenza market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Sanofi S.A., AstraZeneca PLC, Novartis International AG, GlaxoSmithKline plc, Merck KGaA, Moderna Inc., Boehringer Ingelheim International GmbH, Sinovac Biotech Ltd., Daiichi Sankyo Company Limited, CSL Limited, Genentech Inc., Shionogi & Co. Ltd., Emergent BioSolutions Inc., Novavax Inc., BioCryst Pharmaceuticals Inc., Bharat Biotech International Limited, Vaxart Inc., Inovio Pharmaceuticals Inc., SK bioscience Co. Ltd., Mitsubishi Tanabe Pharma Corporation, FluGen Inc., Altimmune Inc.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/seasonal-influenza-global-market-report

How is the Global Seasonal Influenza Market Segemented?

The seasonal influenza market covered in this report is segmented –

1) By Type: Influenza A Virus, Influenza B Virus, Influenza C Virus, Influenza D Virus

2) By Route Of Administration: Parenteral, Oral, Other Route Of Administrations

3) By Distribution Channel: Hospital, Government and institutional supply, Pharmacy, Online

4) By Treatment: Antiviral, Neuraminidase Inhibitors, Vaccination, Other Treatments

Subsegments:

1) By Influenza A Virus: Subtype H1N1, Subtype H3N2, Other Subtypes

2) By Influenza B Virus: Lineage Victoria, Lineage Yamagata

3) By Influenza C Virus: Seasonal C Virus, Non-seasonal C Virus

4) By Influenza D Virus: Animal-associated Influenza D

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=21285&type=smp

Which Geographics are Influencing the Growth of the Seasonal Influenza Market?

North America was the largest region in the seasonal influenza market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the seasonal influenza market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global Seasonal Influenza Market 2025, By The Business Research Company:

Hormone Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/hormone-therapy-global-market-report

Biosimilar Growth Hormones Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/biosimilar-growth-hormone-global-market-report

Biosimilar Hormones Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/biosimilar-hormone-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: